We discussed the potentialities of tumor mutation burden (TMB) as a predictive marker for immunotherapy in breast cancer, also highlighting the limits that have hindered its introduction in the clinical practice. Although some studies have demonstrated the possibility to select patients more responsive to immune-checkpoint inhibitors by evaluating TMB, some issues emerged regarding the complexity of the methodologies for its determination, the costs of the analysis, and the necessity to improve the TMB determination with that of neoantigen identification.
Ravaioli S., Limarzi F., Tumedei M.M., Palleschi M., Maltoni R., Bravaccini S. (2020). Are we ready to use TMB in breast cancer clinical practice?. CANCER IMMUNOLOGY, IMMUNOTHERAPY, 69(10), 1943-1945 [10.1007/s00262-020-02682-w].
Are we ready to use TMB in breast cancer clinical practice?
Limarzi F.;Tumedei M. M.;Palleschi M.;Bravaccini S.
2020
Abstract
We discussed the potentialities of tumor mutation burden (TMB) as a predictive marker for immunotherapy in breast cancer, also highlighting the limits that have hindered its introduction in the clinical practice. Although some studies have demonstrated the possibility to select patients more responsive to immune-checkpoint inhibitors by evaluating TMB, some issues emerged regarding the complexity of the methodologies for its determination, the costs of the analysis, and the necessity to improve the TMB determination with that of neoantigen identification.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
